

Resource Summary Report

Generated by [NIF](#) on Aug 12, 2026

WinNonlin

RRID:SCR_024504

Type: Tool

Proper Citation

WinNonlin (RRID:SCR_024504)

Resource Information

URL: <https://www.certara.com/software/phoenix-pkpd/>

Proper Citation: WinNonlin (RRID:SCR_024504)

Description: Software to automate repetitive analysis steps and is widely considered the industry standard for NCA, TK, and PK/PD modeling. Used as non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling tool.

Synonyms: Phoenix WinNonlin

Resource Type: software application, software resource

Keywords: automate repetitive analysis steps, NCA, TK, PK/PD modeling, non-compartmental analysis, pharmacokinetic/pharmacodynamic, toxicokinetic, modeling tool,

Resource Name: WinNonlin

Resource ID: SCR_024504

Record Creation Time: 20231002T161336+0000

Record Last Update: 20260810T040829+0000

Ratings and Alerts

No rating or validation information has been found for WinNonlin.

No alerts have been found for WinNonlin.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2013 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. *Molecular cancer therapeutics*, 25(7), 1157.

Koyama T, et al. (2026) A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. *Investigational new drugs*.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Wei X, et al. (2026) Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. *Cancer discovery*, 16(6), 1152.

Grafals-Ruiz N, et al. (2026) M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer. *Molecular cancer therapeutics*.

Hoch M, et al. (2026) Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants. *Clinical pharmacology in drug development*, 15(2), e1611.

Jacobs ME, et al. (2026) Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations. *Drug testing and analysis*, 18(1), 139.

Zhang CX, et al. (2026) Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis. *Clinical and translational science*, 19(1), e70453.

Seefried L, et al. (2026) A randomized Phase 1b trial evaluating the pharmacodynamics of ilofotase alfa in adults with hypophosphatasia. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 41(3), 231.

Gareau A, et al. (2026) Serum Symmetric Dimethylarginine as a Predictor of Toxicity of Carboplatin in Dogs. *Veterinary and comparative oncology*, 24(1), 140.

Fabbrini E, et al. (2026) Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers. *The Journal of clinical endocrinology and metabolism*, 111(6), 1628.

Kancharla P, et al. (2026) Potent acridone antimalarial against all three life stages of Plasmodium. *Nature communications*, 17(1).

Shuang Q, et al. (2026) Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta. *mAbs*, 18(1), 2657099.

Wu Q, et al. (2026) Pharmacokinetics of Lekethromycin in Swine Following Intramuscular Administration at Different Doses with a Single Intravenous Reference Dose for Absolute Bioavailability and Matrix Comparison. *Veterinary sciences*, 13(3).

Wu B, et al. (2026) Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. *Journal of medicinal chemistry*, 69(8), 9348.

Xiong L, et al. (2026) Orthosteric-allosteric dual inhibitors of PI5P4K?? with potent antitumor activity in non-small cell lung cancer. *Journal of advanced research*, 84, 1105.

Youssef AS, et al. (2026) A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants. *Clinical pharmacology in drug development*, 15(2), e1615.

Op 't Hoog CJP, et al. (2026) Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. *British journal of clinical pharmacology*, 92(4), 1117.

Otani Y, et al. (2026) One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants. *Advances in therapy*, 43(1), 377.

Wang Y, et al. (2026) Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A. *NPJ systems biology and applications*, 12(1).